| Section | Topic | Key details | Evidence / examples | Citations |
|---|---|---|---|---|
| Primary enzymatic function | Overall reaction | PAM is the only known enzyme that catalyzes C-terminal α-amidation of glycine-extended peptide substrates, a modification required for full activity of many peptide hormones and neuropeptides. In higher animals, PAM is a single bifunctional polypeptide containing two catalytic activities. | Converts peptidyl-Gly precursors into amidated peptide + glyoxylate via a two-step pathway. | (pqac-00000000, pqac-00000001, pqac-00000002, pqac-00000003) |
| Primary enzymatic function | PHM domain reaction | The N-terminal peptidylglycine α-hydroxylating monooxygenase (PHM) domain performs the first, rate-limiting step: stereospecific hydroxylation of the α-carbon of the terminal glycine. This step requires copper, molecular oxygen, and reduced ascorbate. | PHM contains two copper atoms; one mole of ascorbate is consumed per mole of amidated product in assay systems. | (pqac-00000000, pqac-00000001, pqac-00000008) |
| Primary enzymatic function | PAL domain reaction | The C-terminal peptidyl-α-hydroxyglycine α-amidating lyase (PAL) domain cleaves the peptidyl-α-hydroxyglycine intermediate to generate the α-amidated peptide product and glyoxylate. | PAL is the second catalytic activity in the bifunctional enzyme; the intermediate can be relatively stable under acidic granule conditions. | (pqac-00000000, pqac-00000001, pqac-00000011) |
| Primary enzymatic function | Substrate specificity | PAM has broad substrate specificity, producing amides of all 20 amino acids; activity is primarily directed to peptides bearing a C-terminal glycine extension, though non-peptide and fatty acyl glycine substrates have also been described in biochemical studies. | Substrates include classical neuropeptide precursors and, in vitro, fatty acyl glycines such as oleamide precursors. | (pqac-00000004, pqac-00000001, pqac-00000002) |
| Subcellular localization | ER and early secretory pathway | PAM is synthesized with an N-terminal signal peptide and enters the endoplasmic reticulum; its proregion facilitates efficient ER exit and early secretory pathway trafficking. | The proregion promotes secretion/trafficking of soluble proteins and PAM normally exits the ER relatively slowly without it. | (pqac-00000000, pqac-00000012) |
| Subcellular localization | Golgi / TGN | PAM localizes strongly to the perinuclear Golgi region and trans-Golgi network, where peptide processing machinery converges and secretory granules originate. | Immunocytochemistry in AtT-20 cells showed PAM in the perinuclear region near the Golgi; overexpression can trap cargo in the TGN region. | (pqac-00000012, pqac-00000005) |
| Subcellular localization | Secretory granules / neurosecretory vesicles | PAM is packaged into regulated secretory granules and neurosecretory vesicles as both membrane-associated and soluble mono-/bifunctional forms. In atrial myocytes, PAM is a major granule membrane protein. | Subcellular fractionation of brain tissue localized PHM and PAL activities to vesicle-enriched fractions; atrial PAM loss causes a marked granule deficit. | (pqac-00000014, pqac-00000013, pqac-00000010) |
| Subcellular localization | Plasma membrane / extracellular release | Membrane PAM can visit the cell surface during secretion, and soluble PAM forms can be released extracellularly after endoproteolytic processing or secretion from granules. | Soluble PAM proteins are secreted in active form; membrane-associated forms may remain on the surface or be internalized. | (pqac-00000012, pqac-00000014, pqac-00000002) |
| Subcellular localization | Cilia | PAM and amidated peptide products have also been localized to cilia, where they contribute to peptidergic signaling and ectosome-mediated secretion in diverse eukaryotes. | Ciliary localization documented in a 2024 review synthesizing data from algae and metazoans. | (pqac-00000007) |
| Biological substrates | Major amidated peptide classes | PAM-dependent amidation is required for many bioactive peptides, including vasopressin, oxytocin, neuropeptide Y, substance P, cholecystokinin, gastrin, calcitonin, adrenomedullin, CGRP, amylin, PACAP, and VIP. | Reviews note that more than half of peptide hormones require amidation; recent therapeutic discussion lists ADM, CGRP, amylin, NPY, PACAP, VIP and others. | (pqac-00000000, pqac-00000001, pqac-00000003, pqac-00000007) |
| Biological substrates | Functional consequence of amidation | C-terminal amidation typically enhances receptor affinity, protects against carboxypeptidase attack/proteolysis, and is often essential for full biological activity. | Loss of the amide commonly reduces peptide signaling potency; cilia review notes receptor affinity can improve by orders of magnitude. | (pqac-00000004, pqac-00000007, pqac-00000003) |
| Biochemical pathways | Position in peptide maturation pathway | PAM acts late in the regulated secretory pathway after precursor cleavage by subtilisin-like endoproteases and trimming by carboxypeptidase E/H, converting glycine-extended intermediates into mature amidated signals. | PAM is discussed alongside PC1/PC2 and carboxypeptidase E in secretory granule peptide maturation. | (pqac-00000001, pqac-00000002, pqac-00000005) |
| Biochemical pathways | Trafficking and granule biogenesis | Beyond catalysis, PAM participates in secretory pathway organization, including granule formation/maturation and COPI-dependent recycling between Golgi and ER. | In atrial myocytes, PAM loss causes ~13-fold fewer granules and altered proANP handling; COPI-mediated recycling of PAM from cis-Golgi to ER was implicated. | (pqac-00000013) |
| Signaling functions | Cytosolic domain signaling | The cytosolic domain of membrane PAM binds signaling/trafficking regulators including P-CIP2 and Kalirin, linking luminal peptide-processing events to cytoskeletal organization and granule trafficking. | Mutating a PAM cytosolic interaction site restored regulated secretion and prevented abnormal ACTH redistribution in corticotrope cells. | (pqac-00000005) |
| Signaling functions | Oxygen sensing | PAM catalytic output is strikingly oxygen-sensitive in cells, suggesting a monooxygenase-based oxygen-sensing mechanism affecting peptidergic pathways under hypoxia. | Amidation of chromogranin A- and POMC-derived products falls progressively from mild to severe hypoxia. | (pqac-00000006) |
| Recent developments (2023-2025) | Human genetics and endocrine disease | Rare germline loss-of-function PAM variants were enriched in subjects with pituitary hypersecretion; functional testing showed effects on expression, trafficking, splicing, and amidation activity. | Study combined family-based discovery, in vitro functional analysis, and UK Biobank support. | (pqac-00000007) |
| Recent developments (2023-2025) | New amidated signaling peptide space | A 2023 study identified circulating “capped peptides” bearing N-terminal pyroglutamylation and C-terminal amidation, expanding the landscape of potential PAM-dependent signaling molecules. | CAP-TAC1 acted as a nanomolar tachykinin receptor agonist; CAP-GDF15 reduced food intake/body weight in mice. | (pqac-00000007) |
| Recent developments (2023-2025) | Metabolic regulation | In 2024, hypothalamic POMC-neuron work linked increased PAM expression to altered α-MSH synthesis in a lactate/histone-lactylation pathway affecting energy balance and obesity phenotypes. | PAM upregulation was associated with changes in amidated α-MSH production downstream of Fam172a/lactylation changes. | (pqac-00000007) |
| Recent developments (2023-2025) | Biomarker / assay development | A 2023 immunoassay enabled quantification of full-length PAM in human plasma with application to a population-based cohort of 4,850 individuals, supporting biomarker development. | Reported detection limit 189 pg/mL, quantification limit 250 pg/mL, and good assay precision/stability. | (pqac-00000003) |
| Recent developments (2023-2025) | Therapeutic engineering | A 2025 study showed PEGylation markedly prolonged circulating PAM activity in rats, with increased amidating activity persisting up to 7 days after single-dose administration. | Peak activity at 12–24 h after s.c./i.m./i.p. dosing; no obvious adverse effects reported. | (pqac-00000003) |
| Recent developments (2023-2025) | Biotechnology application | Mammalian PAM expressed in plants enabled production of bioactive amidated antimicrobial peptides active against drug-resistant ESKAPE pathogens, illustrating real-world biomanufacturing use. | Amidated AMPs produced in Nicotiana benthamiana showed antibacterial activity and anti-biofilm effects. | (pqac-00000007) |


*Table: This table summarizes the core enzymatic role, trafficking, substrates, signaling functions, and recent translational developments for peptidylglycine α-amidating monooxygenase. It is useful as a compact evidence-backed reference for functional annotation of the Japanese quail PAM ortholog.*